Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma

Most patients with advanced or metastatic urothelial carcinoma do not benefit significantly from Immune checkpoint inhibitors (ICIs) use. A systematic review and meta-analysis of randomized controlled trials to assess the efficacy and activity of ICIs, in terms of Overall Survival (OS), Progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lifang, Wang, Xin, Wang, Shihui, Hua, Linbin, Song, Nan, Hu, Bin, Tong, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939561/
https://www.ncbi.nlm.nih.gov/pubmed/33747636
http://dx.doi.org/10.1080/2162402X.2021.1887551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939561/
https://www.ncbi.nlm.nih.gov/pubmed/33747636
http://dx.doi.org/10.1080/2162402X.2021.1887551

Ejemplares similares